181 related articles for article (PubMed ID: 16127163)
1. Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model.
Shannon P; Sabha N; Lau N; Kamnasaran D; Gutmann DH; Guha A
Am J Pathol; 2005 Sep; 167(3):859-67. PubMed ID: 16127163
[TBL] [Abstract][Full Text] [Related]
2. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas.
Ding H; Roncari L; Shannon P; Wu X; Lau N; Karaskova J; Gutmann DH; Squire JA; Nagy A; Guha A
Cancer Res; 2001 May; 61(9):3826-36. PubMed ID: 11325859
[TBL] [Abstract][Full Text] [Related]
3. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model.
Ding H; Shannon P; Lau N; Wu X; Roncari L; Baldwin RL; Takebayashi H; Nagy A; Gutmann DH; Guha A
Cancer Res; 2003 Mar; 63(5):1106-13. PubMed ID: 12615729
[TBL] [Abstract][Full Text] [Related]
4. Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice.
Weissenberger J; Steinbach JP; Malin G; Spada S; Rülicke T; Aguzzi A
Oncogene; 1997 May; 14(17):2005-13. PubMed ID: 9160879
[TBL] [Abstract][Full Text] [Related]
5. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
[TBL] [Abstract][Full Text] [Related]
6. No complementation between TP53 or RB-1 and v-src in astrocytomas of GFAP-v-src transgenic mice.
Maddalena AS; Hainfellner JA; Hegi ME; Glatzel M; Aguzzi A
Brain Pathol; 1999 Oct; 9(4):627-37. PubMed ID: 10517501
[TBL] [Abstract][Full Text] [Related]
7. Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice.
Theurillat JP; Hainfellner J; Maddalena A; Weissenberger J; Aguzzi A
Am J Pathol; 1999 Feb; 154(2):581-90. PubMed ID: 10027415
[TBL] [Abstract][Full Text] [Related]
8. Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo.
Huang ZY; Baldwin RL; Hedrick NM; Gutmann DH
Oncogene; 2002 Feb; 21(9):1325-34. PubMed ID: 11857076
[TBL] [Abstract][Full Text] [Related]
9. Mouse glioma gene expression profiling identifies novel human glioma-associated genes.
Gutmann DH; Huang ZY; Hedrick NM; Ding H; Guha A; Watson MA
Ann Neurol; 2002 Mar; 51(3):393-405. PubMed ID: 11891838
[TBL] [Abstract][Full Text] [Related]
10. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation.
Bajenaru ML; Zhu Y; Hedrick NM; Donahoe J; Parada LF; Gutmann DH
Mol Cell Biol; 2002 Jul; 22(14):5100-13. PubMed ID: 12077339
[TBL] [Abstract][Full Text] [Related]
11. Loss of GFAP expression in high-grade astrocytomas does not contribute to tumor development or progression.
Wilhelmsson U; Eliasson C; Bjerkvig R; Pekny M
Oncogene; 2003 May; 22(22):3407-11. PubMed ID: 12776191
[TBL] [Abstract][Full Text] [Related]
12. GATA6 is an astrocytoma tumor suppressor gene identified by gene trapping of mouse glioma model.
Kamnasaran D; Qian B; Hawkins C; Stanford WL; Guha A
Proc Natl Acad Sci U S A; 2007 May; 104(19):8053-8. PubMed ID: 17463088
[TBL] [Abstract][Full Text] [Related]
13. J1-31 protein expression in astrocytes and astrocytomas.
Shuangshoti S; Thorner PS; Ruangvejvorachai P; Saha B; Groshen S; Taylor CR; Malhotra S; Imam SA
Neuropathology; 2009 Oct; 29(5):521-7. PubMed ID: 19019178
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
15. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo.
Dai C; Celestino JC; Okada Y; Louis DN; Fuller GN; Holland EC
Genes Dev; 2001 Aug; 15(15):1913-25. PubMed ID: 11485986
[TBL] [Abstract][Full Text] [Related]
16. Transformation of astrocytes in transgenic mice expressing SV40 T antigen under the transcriptional control of the glial fibrillary acidic protein promoter.
Danks RA; Orian JM; Gonzales MF; Tan SS; Alexander B; Mikoshiba K; Kaye AH
Cancer Res; 1995 Oct; 55(19):4302-10. PubMed ID: 7671240
[TBL] [Abstract][Full Text] [Related]
17. Mouse astrocytoma models: embryonic stem cell mediated transgenesis.
Ding H; Guha A
J Neurooncol; 2001 Jul; 53(3):289-96. PubMed ID: 11718261
[TBL] [Abstract][Full Text] [Related]
18. Expression and regulation of neuropilin-1 in human astrocytomas.
Ding H; Wu X; Roncari L; Lau N; Shannon P; Nagy A; Guha A
Int J Cancer; 2000 Nov; 88(4):584-92. PubMed ID: 11058875
[TBL] [Abstract][Full Text] [Related]
19. Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo.
Holland EC; Li Y; Celestino J; Dai C; Schaefer L; Sawaya RA; Fuller GN
Am J Pathol; 2000 Sep; 157(3):1031-7. PubMed ID: 10980141
[TBL] [Abstract][Full Text] [Related]
20. Pilocytic astrocytomas do not show most of the genetic changes commonly seen in diffuse astrocytomas.
Cheng Y; Pang JC; Ng HK; Ding M; Zhang SF; Zheng J; Liu DG; Poon WS
Histopathology; 2000 Nov; 37(5):437-44. PubMed ID: 11119125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
